Trial Profile
A 24 weeks multicentre, randomized, double-blind, placebo-controlled, parallel group, study to evaluate the efficacy, safety and tolerability of intravenous IG-8801 20 mg and 40 mg in subjects with chronic low back pain
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Mar 2016
Price :
$35
*
At a glance
- Drugs Olpadronic acid (Primary)
- Indications Back pain
- Focus Therapeutic Use
- Sponsors Gador
- 23 Mar 2016 New trial record